CJC-1295 With DAC (5mg)

Description

CJC-1295 With DAC (Drug Affinity Complex) is a GHRH analogue based on the first 29 amino acids of GHRH, modified at four positions for stability and conjugated with a lysine-maleimidoproprionic acid linker that binds endogenous albumin after injection. This albumin binding dramatically extends the peptide’s half-life to approximately 6–8 days in human pharmacokinetic studies, compared to minutes for native GHRH.

Why Researchers Select CJC-1295 With DAC

The DAC modification transforms the short-acting GHRH pulse signal into a prolonged, sustained elevation. This creates a fundamentally different research model compared to pulsatile GH secretagogues: rather than studying GH pulse dynamics, researchers use the DAC version to study tonic, sustained GH pathway activation, chronic IGF-1 elevation models, or long-acting GHRH receptor occupancy. The 5mg quantity suits preliminary characterization of the extended-release pharmacology profile.

Common Research Applications

• Sustained GHRH receptor occupancy and downstream signaling studies
• Chronic GH and IGF-1 elevation models
• Albumin-mediated extended half-life pharmacokinetic research
• Comparison of pulsatile vs. tonic GH secretion phenotypes

Molecular Profile

• MW: ~3,647 g/mol | CAS: 863288-34-0 (base) | Purity: ≥98% HPLC

For Research Use Only. Not for human or veterinary use.